[68Ga]Ga-P15-041 PET/CT in Variety of Bone Tumors
Launched by FIRST AFFILIATED HOSPITAL OF FUJIAN MEDICAL UNIVERSITY · Jun 7, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new imaging technique using a special substance called [68Ga]Ga-P15-041 to help doctors see and identify different types of bone tumors, including both primary tumors (those that start in the bone) and metastatic tumors (those that spread to the bone from other parts of the body). The goal is to improve early diagnosis, which is crucial for starting effective treatment. This trial is currently recruiting participants aged 18 to 75 who either have suspected or confirmed bone tumors and can provide recent imaging results, such as a bone scan or CT scan.
If you join the study, you'll receive the new imaging test, which is designed to highlight areas of concern in your bones. To participate, you should not be pregnant, breastfeeding, or allergic to a certain type of medication called bisphosphonates. Overall, this trial aims to advance our understanding of bone tumors and potentially lead to better treatment options in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • suspected or confirmed primary bone tumors or metastatic bone tumors
- • signed written consent
- • available other examinations such as bone scan or enhanced CT within 2 weeks
- Exclusion Criteria:
- • pregnancy
- • breastfeeding
- • known allergy against bisphosphonate
About First Affiliated Hospital Of Fujian Medical University
The First Affiliated Hospital of Fujian Medical University is a leading medical institution dedicated to advancing healthcare through innovative clinical research and education. As a premier sponsor of clinical trials, the hospital is committed to improving patient outcomes and contributing to medical knowledge across various specialties. With a robust infrastructure and a multidisciplinary team of experienced researchers and healthcare professionals, the hospital ensures the ethical conduct and scientific rigor of its trials, fostering collaboration with global research communities. Its mission is to enhance the quality of care through evidence-based practices and to support the development of novel therapies that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fuzhou, Fujian, China
Patients applied
Trial Officials
Weibing Miao, MD
Principal Investigator
First Affiliated Hospital of Fujian Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported